Flywheel for

Flywheel’s imaging data management and analysis platform is purpose-built for BioPharma companies like Bristol Myers Squibb who are conducting multisite neuroscience and oncology programs and need to accelerate drug development and research workflows

We’re working with 10 of the top 20 biopharma companies to ensure they maximize the value of their imaging data for secondary endpoint analysis, biomarker extraction, and faster clinical trial decisions. Connect with our experts to explore how your team can:

Learn how multicenter studies such as BMS’ ADEPT-2 trial (NCT06126224) could benefit from a validated imaging platform that provides audit trails, project locking and more — for FDA compliance and reproducible results. 

Fill out the form and we’ll reach out within 1 business day.